Rising 426% in 2017, Esperion benefited from successful trial results for its cholesterol-reducing drug candidate. Best Under-$10 Value Plays
Trading at just $3.05 at the start of the year, it climbed to $16.40 by year-end—a 438% return . Its growth was fueled by a major collaboration agreement with a Big Pharma partner. best cheap stocks to buy 2017
Analysts frequently highlighted "nominally cheap" stocks that combined low share prices with strong fundamental value. Rising 426% in 2017, Esperion benefited from successful